Endonovo Therapeutics annual gross profit
2013
2014
2015
2018
2019
2020
2021
2022
2023
2024
Endonovo Therapeutics Gross Profit Growth & History (ENDV)
Endonovo Therapeutics's gross profit was $3,334 for fiscal 2024.
View full Endonovo Therapeutics company overviewEndonovo Therapeutics annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $3,334 | −$129,068 | −97.48% |
| 2023 | 2023-12-31 | $132,402 | $7,037 | +5.61% |
| 2022 | 2022-12-31 | $125,365 | $67,245 | +115.70% |
| 2021 | 2021-12-31 | $58,120 | −$42,307 | −42.13% |
| 2020 | 2020-12-31 | $100,427 | −$116,352 | −53.67% |
| 2019 | 2019-12-31 | $216,779 | $146,446 | +208.22% |
| 2018 | 2018-12-31 | $70,333 | — | — |
| 2015 | 2015-12-31 | $2,103 | −$6,604 | −75.85% |
| 2014 | 2014-12-31 | $8,707 | −$196 | −2.20% |
| 2013 | 2013-12-31 | $8,903 | — | — |
Endonovo Therapeutics quarterly gross profit
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q4.15
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.24
Q1.25
Q2.25
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q4 2024 | 2024-12-31 | −$1 | — | — |
| Q3 2023 | 2023-09-30 | $693 | −$6,240 | −90.00% |
| Q2 2023 | 2023-06-30 | $45,200 | $44,933 | +16828.84% |
| Q1 2023 | 2023-03-31 | $83,544 | $81,976 | +5228.06% |
| Q4 2022 | 2022-12-31 | $116,597 | $125,142 | — |
| Q3 2022 | 2022-09-30 | $6,933 | $2,246 | +47.92% |
| Q2 2022 | 2022-06-30 | $267 | −$29,517 | −99.10% |
| Q1 2022 | 2022-03-31 | $1,568 | −$30,626 | −95.13% |
| Q4 2021 | 2021-12-31 | −$8,545 | $27,004 | — |
| Q3 2021 | 2021-09-30 | $4,687 | −$34,533 | −88.05% |
| Q2 2021 | 2021-06-30 | $29,784 | −$3,547 | −10.64% |
| Q1 2021 | 2021-03-31 | $32,194 | −$31,231 | −49.24% |
| Q4 2020 | 2020-12-31 | −$35,549 | −$136,817 | — |
| Q3 2020 | 2020-09-30 | $39,220 | −$5,894 | −13.06% |
| Q2 2020 | 2020-06-30 | $33,331 | $175 | +0.53% |
| Q1 2020 | 2020-03-31 | $63,425 | $26,184 | +70.31% |
| Q4 2019 | 2019-12-31 | $101,268 | $67,205 | +197.30% |
| Q3 2019 | 2019-09-30 | $45,114 | $28,120 | +165.47% |
| Q2 2019 | 2019-06-30 | $33,156 | $20,852 | +169.47% |
| Q1 2019 | 2019-03-31 | $37,241 | $30,269 | +434.15% |
| Q4 2018 | 2018-12-31 | $34,063 | — | — |
| Q3 2018 | 2018-09-30 | $16,994 | — | — |
| Q2 2018 | 2018-06-30 | $12,304 | — | — |
| Q1 2018 | 2018-03-31 | $6,972 | — | — |
| Q4 2015 | 2016-03-31 | $0 | −$1,921 | — |
| Q4 2015 | 2015-12-31 | $0 | $15,929 | — |
| Q3 2015 | 2015-09-30 | −$400 | −$5,213 | — |
| Q2 2015 | 2015-06-30 | $582 | −$9,930 | −94.46% |
| Q1 2015 | 2015-03-31 | $1,921 | −$7,390 | −79.37% |
| Q4 2014 | 2014-12-31 | −$15,929 | — | — |
| Q3 2014 | 2014-09-30 | $4,813 | — | — |
| Q2 2014 | 2014-06-30 | $10,512 | — | — |
| Q1 2014 | 2014-03-31 | $9,311 | — | — |
Endonovo Therapeutics gross profit trends
Over the last five fiscal years, Endonovo Therapeutics's gross profit decreased from $216,779 to $3,334, a change of −$213,445. The latest reported quarter, Q2 2025, shows $0.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Endonovo Therapeutics source filings ↗